{"id":273,"date":"2026-11-17T01:13:44","date_gmt":"2026-11-17T01:13:44","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=273"},"modified":"2026-11-17T01:13:44","modified_gmt":"2026-11-17T01:13:44","slug":"giredestrant-wilserdly-drug-intelligence-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/giredestrant-wilserdly-drug-intelligence-dossier\/","title":{"rendered":"Giredestrant (WILSERDLY) \u2014 Drug Intelligence Dossier"},"content":{"rendered":"\n<p><strong>Mechanism:<\/strong> Giredestrant (GDC-9545) is an oral, non-steroidal, highly potent <strong>selective estrogen receptor degrader (SERD)<\/strong>. It binds the ER&alpha; ligand-binding domain and antagonises the transcriptional activity of both wild-type and mutant ESR1 (e.g. Y537S, D538G) while inducing degradation of the ER&alpha; protein with <em>no residual agonism<\/em> &mdash; the deliberate contrast to first-generation SERMs\/SERDs. Structurally it is a (1R,3R)-<em>cis<\/em>-1-aryl-3-methyl-tetrahydro-&beta;-carboline whose basic 1-(3-fluoropropyl)azetidin-3-ylamino side chain projects out of the pocket to destabilise helix 12 and lock the receptor in its antagonist conformation; recent work shows it also <em>immobilises ER&alpha; on chromatin<\/em>, a degradation-independent contribution to antitumour effect. Reporter potency is sub-nanomolar (ER&alpha; antagonist IC<sub>50<\/sub> &asymp; 0.05 nM; MCF-7 antiproliferative EC<sub>50<\/sub> &asymp; 0.4 nM), with activity retained in endocrine-resistant and Y537S-mutant lines and wide off-target margins (hERG IC<sub>50<\/sub> 6.1 &micro;M). The approved regimen pairs it with <strong>everolimus<\/strong> because co-targeting ER and mTORC1 is synergistic and blunts the dominant PI3K\/AKT\/mTOR escape route after CDK4\/6 inhibition. ER&alpha; co-crystal: PDB 7MSA. <em>Refs: J. Med. Chem. 2021 (PMID 34251202); Zhou W et al., Cell Chem. Biol. 2026 (PMID 42161265).<\/em><\/p>\n\n\n<p><strong>t&frac12;:<\/strong> 43 h at steady state (CV 15%), apparent clearance 5.9 L\/h &mdash; a long half-life that comfortably supports once-daily dosing with a forgiving missed-dose profile &middot; <strong>Tmax:<\/strong> median 3 h; steady state by Day 8; absolute oral bioavailability 58%; no clinically significant food effect (PI &sect;12.3).<\/p>\n\n\n<h2 class=\"wp-block-heading\">Synthesis Route of the Originator<\/h2>\n\n\n<p>The commercial route is disclosed in <strong>WO2019245974A1 \/ US10,954,234 B2<\/strong> (Genentech\/Roche, priority 2018) and by the Roche process group (Xu et al., <em>Org. Process Res. Dev.<\/em> 2022, 26, 568&ndash;582). Giredestrant has two stereocentres, both <em>R<\/em>, and the whole route is organised around setting them cheaply. <strong>C3 (the methyl-bearing carbon) is imported, not made:<\/strong> Boc-D-alaninol is converted to a chiral cyclic sulfamidate and opened by a low-order indolyl cuprate (indole \/ CuCl \/ MeMgCl, &minus;20 &deg;C) with <strong>97:3 C3\/N1 regioselectivity<\/strong> &mdash; deliberately replacing the classical, hazardous nitroalkane route to chiral &alpha;-substituted tryptamines. Boc removal gives (R)-&alpha;-methyltryptamine in 99.2% ee; a cyclic-sulfate alkylation then installs the 2,2-difluoro-3-hydroxypropyl N2 arm in one step (97.6%). In parallel, 4-bromo-2,6-difluorobenzaldehyde is masked as its diethyl acetal, coupled with 1-(3-fluoropropyl)azetidin-3-amine under <strong>BrettPhos Pd G3<\/strong> (1 mol% Pd), and unmasked to the convergent aldehyde (84.3%). <strong>C1 is set last and thermodynamically:<\/strong> a crystallization-driven diastereoselective <strong>Pictet&ndash;Spengler<\/strong> with L-tartaric acid (EtOH, 70 &deg;C, seeded, 2 days) funnels the <em>cis\/trans<\/em> mixture into the single (1R,3R)-tartrate &mdash; the registered drug substance &mdash; in 78% yield, with <em>no chromatography and no chiral resolution<\/em>. This tartaric-acid ring closure, acting as both catalyst and crystallising counterion, is the keystone of the process IP and the economics.<\/p>\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"2444\" height=\"1639\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_scheme.png\" alt=\"\" class=\"wp-image-270\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_scheme.png 2444w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_scheme-300x201.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_scheme-1024x687.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_scheme-768x515.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_scheme-1536x1030.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_scheme-2048x1373.png 2048w\" sizes=\"auto, (max-width: 2444px) 100vw, 2444px\" \/><figcaption class=\"wp-element-caption\">Redrawn 5-step convergent manufacturing route (WO2019245974A1, Example 8): a chiral &beta;-carboline amine fragment and a Buchwald aryl-aldehyde fragment converge in a crystallization-driven diastereoselective Pictet&ndash;Spengler. Redrawn by Astinova Bio Labs.<\/figcaption><\/figure>\n\n\n<p><em>Reagents and conditions:<\/em> (1) imidazole, SOCl<sub>2<\/sub>, DCM, &minus;5&rarr;0 &deg;C; then RuCl<sub>3<\/sub>&middot;xH<sub>2<\/sub>O (cat.) \/ Oxone, 0&rarr;22 &deg;C &mdash; 91.8% over two steps. (2) indole (1.5 eq), CuCl (1.3 eq), MeMgCl (1.33 eq), DCM, &minus;20&rarr;&minus;10 &deg;C &mdash; C3:N1 97:3 (the chloride-only Mg\/Cu system is essential; MeMgBr\/CuCl collapses to 45:54). (3) HCl\/MeOH, 0&rarr;30 &deg;C &mdash; 99.2% ee, inherited intact from Boc-D-alaninol. (4) 5,5-difluoro-1,3,2-dioxathiane 2,2-dioxide (1.07 eq), K<sub>2<\/sub>CO<sub>3<\/sub>, MeCN, 80 &deg;C; then p-TsOH&middot;H<sub>2<\/sub>O \/ H<sub>2<\/sub>O &mdash; 97.6%. (i) HC(OEt)<sub>3<\/sub>, p-TsOH, toluene. (ii) azetidine&middot;EDSA freebased with DBU, NaOtBu, BrettPhos Pd G3 (1 mol%), toluene, 60 &deg;C; SiliaMetS Thiol scavenge. (iii) AcOH \/ H<sub>2<\/sub>O &mdash; 84.3%. (5) L-tartaric acid (1.5 eq), EtOH, 70 &deg;C, 0.5 mol% seed, 2 days &mdash; 78%, isolated directly as the (2R,3R)-tartrate. [WO2019245974A1, Examples 5, 6 and 8.]<\/p>\n\n\n<h2 class=\"wp-block-heading\">Key intermediates<\/h2>\n\n\n<p>All intermediates trace to cheap chiral-pool and commercial building blocks; the single physical stereocentre (C3) is carried with retention as (R) throughout, and C1 is set only at the final crystallisation.<\/p>\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"2436\" height=\"1146\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_intermediates.png\" alt=\"\" class=\"wp-image-271\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_intermediates.png 2436w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_intermediates-300x141.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_intermediates-1024x482.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_intermediates-768x361.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_intermediates-1536x723.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/gir_intermediates-2048x963.png 2048w\" sizes=\"auto, (max-width: 2436px) 100vw, 2436px\" \/><figcaption class=\"wp-element-caption\">Key building blocks and intermediates of the giredestrant manufacturing route (structures rendered by Astinova Bio Labs with RDKit).<\/figcaption><\/figure>\n\n\n<figure class=\"wp-block-table\"><table><thead><tr><th>Label<\/th><th>Name<\/th><th>Role \/ sourcing<\/th><\/tr><\/thead><tbody><tr><td>SM-1<\/td><td>Boc-D-alaninol<\/td><td>Chiral-pool source of the C3 (R) centre &mdash; no asymmetric catalysis anywhere in the route.<\/td><\/tr><tr><td>INT-1<\/td><td>(R)-cyclic sulfamidate<\/td><td>From alaninol (imidazole\/SOCl<sub>2<\/sub>; RuCl<sub>3<\/sub>\/Oxone), 91.8% over 2 steps.<\/td><\/tr><tr><td>INT-2<\/td><td>Boc-(R)-&alpha;-methyltryptamine<\/td><td>Cu(I)-mediated regioselective C3 indole alkylation, C3:N1 97:3.<\/td><\/tr><tr><td>INT-3<\/td><td>(R)-&alpha;-methyltryptamine<\/td><td>Boc removal (HCl\/MeOH); 99.2% ee.<\/td><\/tr><tr><td>SM-2<\/td><td>5,5-difluoro cyclic sulfate<\/td><td>Electrophile that installs the gem-difluoro N2 arm in one step.<\/td><\/tr><tr><td>INT-4<\/td><td>(R)-2,2-difluoro amino alcohol<\/td><td>Cyclic-sulfate alkylation, 97.6% &mdash; the chiral secondary amine entering the Pictet&ndash;Spengler.<\/td><\/tr><tr><td>SM-3<\/td><td>1-(3-fluoropropyl)azetidin-3-amine<\/td><td>Shipped as the crystalline EDSA salt (note: 1-bromo-3-fluoropropane is an ICH M7 genotoxic alkylator requiring control).<\/td><\/tr><tr><td>SM-4<\/td><td>4-bromo-2,6-difluorobenzaldehyde<\/td><td>Supplies both ortho-fluorines of the pharmacophore and the C&ndash;Br handle.<\/td><\/tr><tr><td>INT-5<\/td><td>convergent aldehyde<\/td><td>BrettPhos Pd G3 Buchwald&ndash;Hartwig on the acetal, then hydrolysis; 84.3%.<\/td><\/tr><tr><td>API<\/td><td>Giredestrant (free base)<\/td><td>Crystallization-driven diastereoselective Pictet&ndash;Spengler with L-tartaric acid, 78%; isolated as the (2R,3R)-tartrate.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n<h2 class=\"wp-block-heading\">Crystal Forms, Salts &amp; Solid-State Profile<\/h2>\n\n\n<p><strong>Drug substance:<\/strong> the marketed API is giredestrant <strong>L-(2R,3R)-tartrate<\/strong>, not the free base (PI &sect;11: C<sub>27<\/sub>H<sub>31<\/sub>F<sub>5<\/sub>N<sub>4<\/sub>O &middot; C<sub>4<\/sub>H<sub>6<\/sub>O<sub>6<\/sub>; 522.55 g\/mol free base, 672.64 g\/mol salt). <strong>Product:<\/strong> a single 30 mg capsule strength (= 38.62 mg tartrate; pink cap \/ brown body, printed &ldquo;GIR 30&rdquo;). Absolute oral bioavailability is 58%, so the salt choice is doing real work on dissolution\/permeability &mdash; and because the tartrate is the diastereoselectivity-driving counterion, a competing salt form would also require a different route. Roche claims an extensive solid-form estate in WO2019245974A1 (free base, tartrate, fumarate, malonate; crystalline Forms A&ndash;G, Form 1\/2, amorphous), with a second-generation family (CN119156386A, priority 2022) extending cover toward ~2042.<\/p>\n\n\n<h2 class=\"wp-block-heading\">Clinical &amp; Regulatory Profile<\/h2>\n\n\n<p><strong>Approval (US):<\/strong> 2026-11-16, brand <strong>WILSERDLY<\/strong>, as a regular (traditional) approval via Project Orbis &mdash; four weeks ahead of the goal date. <strong>Indication (PI &sect;1):<\/strong> in combination with everolimus, for adults with ER+, HER2&minus;, <strong>ESR1-mutated<\/strong> locally advanced or metastatic breast cancer (FDA-authorized test) whose disease recurred during\/after adjuvant endocrine therapy or progressed on &ge;1 endocrine-based regimen in the metastatic setting &mdash; practically a post-CDK4\/6-inhibitor, ctDNA-ESR1-selected 2L\/3L position, and the <strong>first oral SERD approved as a combination with an mTOR inhibitor<\/strong> rather than as monotherapy. <strong>Companion diagnostic:<\/strong> FoundationOne Liquid CDx (plasma ctDNA ESR1 ligand-binding-domain mutations).<\/p>\n\n\n<p><strong>Pivotal trial &mdash; evERA<\/strong> (NCT05306340, Phase III, N=373): in the ESR1-mutated population, giredestrant + everolimus gave <strong>PFS HR 0.38<\/strong> (95% CI 0.27&ndash;0.54, p&lt;0.0001), medians <strong>10.0 vs 5.5 months<\/strong>, ORR 27% vs 14% (Mayer EL et al., <em>N Engl J Med<\/em> 2026;395(13):1285&ndash;1298; PMID 42814929). A separate early-stage adjuvant application (lidERA; iDFS HR 0.70) is under Priority Review with a PDUFA date of 2026-11-30.<\/p>\n\n\n<h2 class=\"wp-block-heading\">PK \/ ADME highlights<\/h2>\n\n\n<p>t&frac12; 43 h (once-daily dosing); Tmax ~3 h; F 58%; plasma protein binding &gt;98%. <strong>Primarily CYP3A-metabolised<\/strong> &mdash; strong CYP3A inhibitors (itraconazole AUC &uarr;~4&times;) and inducers (carbamazepine AUC &darr;~24%) are to be avoided. No clinically significant food effect, and no dose adjustment for hepatic impairment (Child-Pugh A&ndash;C) or mild&ndash;moderate renal impairment. The class cardiac signal is <em>bradycardia<\/em> (mean HR &darr;~7 bpm, plateauing by 2 weeks), not QT prolongation (hERG IC<sub>50<\/sub> 6.1 &micro;M).<\/p>\n\n\n<h2 class=\"wp-block-heading\">Key references &amp; source trail<\/h2>\n\n\n<ul class=\"wp-block-list\"><li>FDA oncology approval notice &mdash; giredestrant + everolimus (ER+, HER2&minus;, ESR1-mutated advanced breast cancer), action date 2026-11-16.<\/li><li>WILSERDLY (giredestrant) capsules, US Prescribing Information, rev. 11\/2026.<\/li><li>Mayer EL, Tolaney SM, Martin M, et al.; evERA Breast Cancer Investigators. Giredestrant plus Everolimus in Advanced Breast Cancer. <em>N Engl J Med<\/em> 2026;395(13):1285&ndash;1298. PMID 42814929.<\/li><li>Giredestrant discovery &amp; medicinal chemistry: <em>J. Med. Chem.<\/em> 2021 (PMID 34251202).<\/li><li>Zhou W et al., chromatin immobilisation by giredestrant, <em>Cell Chem. Biol.<\/em> 2026 (PMID 42161265).<\/li><li>Process chemistry: Xu et al., <em>Org. Process Res. Dev.<\/em> 2022, 26, 568&ndash;582 (DOI 10.1021\/acs.oprd.1c00263); patent WO2019245974A1 \/ US10,954,234 B2.<\/li><\/ul>\n\n","protected":false},"excerpt":{"rendered":"<p>A medicinal-chemistry dossier on giredestrant (WILSERDLY) \u2014 the first oral SERD approved with everolimus for ER+\/HER2\u2212, ESR1-mutated advanced breast cancer: mechanism, the crystallization-driven Pictet\u2013Spengler manufacturing route, key intermediates, and the evERA data.<\/p>\n","protected":false},"author":1,"featured_media":269,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[95,97,94,93,91,37,96,92],"class_list":["post-273","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fda-approved-small-molecules","tag-breast-cancer","tag-buchwald-coupling","tag-esr1","tag-estrogen-receptor","tag-giredestrant","tag-oncology","tag-pictet-spengler","tag-serd"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=273"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/273\/revisions"}],"predecessor-version":[{"id":275,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/273\/revisions\/275"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/269"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}